

Trimethobenzamide (TIGAN) oral capsule

Criteria for Use

June 2023

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the [PBM INTRAnet](#) site for further information.

Inclusion Criteria

All of the following criteria must be met.

- Care provided by a VA or VA Community Care neurologist
- Prescribed in conjunction with apomorphine¹

Footnote

1. Trimethobenzamide is recommended to control nausea and vomiting that can result from apomorphine treatment

Prepared: June 2023. Contact: Natasha Antonovich PharmD, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)
